← Back to Search

Treatment for Brain Tumor (VIGILANT Trial)

N/A
Waitlist Available
Research Sponsored by Arbor Pharmaceuticals, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 3 years
Awards & highlights

Summary

This is a prospective, observational registry in patients who have been prescribed Gliadel Wafer by the physician as part of usual care.

Eligible Conditions
  • Brain Tumor

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 3 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 3 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
To evaluate the disease-specific survival rate for patients treated with Gliadel Wafer
To evaluate the overall survival rate for patients treated with Gliadel Wafer
To evaluate the progression-free survival rate for patients treated with Gliadel Wafer
Secondary study objectives
To evaluate change in patient health status over time via a practitioner/proxy reported scale
To evaluate change in patient health status over time via patient reported outcomes (PRO)
To evaluate events of interest (EOI) in patients treated with Gliadel Wafer.
+3 more
Other study objectives
To evaluate health care utilization though length of hospital stays for the primary procedure and any subsequent hospitalizations in patients treated with Gliadel Wafer

Find a Location

Who is running the clinical trial?

Arbor Pharmaceuticals, Inc.Lead Sponsor
16 Previous Clinical Trials
2,043 Total Patients Enrolled
Evan Scullin, MDStudy ChairArbor Pharmaceuticals, LLC is a subsidiary of Azurity Pharmaceuticals, Inc."
1 Previous Clinical Trials
40 Total Patients Enrolled
~33 spots leftby Dec 2025